Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director · CHIEF EXECUTIVE OFFICER | August 17, 2026 | August 18, 2026 |
| Ra Pharmaceuticals, Inc.RARX · Entity 150034 | Director · 10% owner | June 20, 2017 | June 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 294,379 |
Reported balance
After 2026-08-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 2,230 · Balance 294,379 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
F2: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.
Ra Pharmaceuticals, Inc.
Report date June 20, 2017 · Filed June 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $22.37 · Expires 2027-06-20 | Direct | 15,000 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 15,000 · Balance 15,000 F1: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018. F2: The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018.
F2: The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries C Convertible Preferred Stock · Derivative | 664,660 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 20 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 664,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries C Convertible Preferred Stock · Derivative | 18,705 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 19 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 18,705 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries C Convertible Preferred Stock · Derivative | 137,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 18 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 137,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries C Convertible Preferred Stock · Derivative | 10,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 17 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,529 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries B Convertible Preferred Stock · Derivative | 11,110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 16 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 11,110 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries B Convertible Preferred Stock · Derivative | 150,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 15 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 150,801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries B Convertible Preferred Stock · Derivative | 8,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 14 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 8,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries B Convertible Preferred Stock · Derivative | 59,998 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 13 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 59,998 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 39,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 12 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 39,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 683,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 11 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 683,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 222,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 10 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 222,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,633,743 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 9 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,633,743 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 78,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · derivative · entry 8 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 111,528 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 7 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 120,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F12 · balance_after: Includes 8,684 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 22,000 | $19.00 | $418,000.00 |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 6 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,000 F11 · ownership.nature: The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 1,498,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 5 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,023,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F10 · balance_after: Includes 146,485 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 378,000 | $19.00 | $7,182,000.00 |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 4 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 378,000 F9 · ownership.nature: The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 249,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 3 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 309,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · balance_after: Includes 59,590 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F8 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 1,831,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 2 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,268,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · balance_after: Includes 437,060 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F6 · ownership.nature: The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 88,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019931 · doc4.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · balance_after: Includes 18,516 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 23:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 24,009 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019579 · doc4.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,009 Underlying: Common Stock · 24,009 shares Expires 2030-07-16 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on August 16, 2020. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 23:41 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOptions to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $22.37 | $0.00 |
DisclosureSEC source: 0001104659-17-041012 · a4.xml · derivative · entry 1 Lettmann Jason · CIK 0001688269 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-20 F1 · derivative.exercise_date: On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018. F2 · ownership.direct: The reporting person is a member of Morgenthaler Advisors IX, LLC ("MA IX"), which is the investment adviser of Morgenthaler Venture Partners IX, LP ("MVP IX"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionSeries B-2 Preferred Stock · Derivative | 481,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · derivative · entry 20 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 68,786 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · derivative.exercise_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · derivative.expiration_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionSeries B-1 Preferred Stock · Derivative | 3,533,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · derivative · entry 19 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 504,839 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · derivative.exercise_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · derivative.expiration_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionSeries B-2 Preferred Stock · Derivative | 517,617 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · derivative · entry 18 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 73,945 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · derivative.exercise_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · derivative.expiration_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionSeries B-1 Preferred Stock · Derivative | 3,798,914 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · derivative · entry 17 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 542,702 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · derivative.exercise_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · derivative.expiration_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionSeries B-2 Preferred Stock · Derivative | 3,408,439 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · derivative · entry 16 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 486,919 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · derivative.exercise_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F5 · derivative.expiration_date: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionSeries B-1 Preferred Stock · Derivative | 3,664,071 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · derivative · entry 15 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 523,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · derivative.exercise_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F4 · derivative.expiration_date: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionSeries A Preferred Stock · Derivative | 9,744,916 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · derivative · entry 14 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,392,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F3 · price: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F3 · derivative.exercise_date: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F3 · derivative.expiration_date: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | OtherWarrants to Purchase Common Stock · Derivative | 63,019 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · derivative · entry 13 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 63,019 shares Expires 2022-04-01 F2 · derivative.exercise_price: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares. F2 · derivative.exercise_date: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | PurchaseCommon Stock | 15,633 | $13.00 | $203,229.00 |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 12 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,066,503 F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | PurchaseCommon Stock | 114,752 | $13.00 | $1,491,776.00 |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 11 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,050,870 F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | PurchaseCommon Stock | 263,538 | $13.00 | $3,425,994.00 |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 10 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,936,118 F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionCommon Stock | 68,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 9 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,672,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionCommon Stock | 504,839 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 8 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,603,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionCommon Stock | 73,945 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 7 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,098,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F7 · ownership.nature: Shares held by Lightstone Ventures (A), L.P. LSV GP is the General Partner of Lightstone Ventures (A), L.P. ("LSV-A"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionCommon Stock | 542,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 6 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,025,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F6 · ownership.nature: Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. ("LSV"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionCommon Stock | 486,919 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 5 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,482,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionCommon Stock | 523,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 4 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,995,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | ConversionCommon Stock | 1,392,130 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 3 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,471,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | SaleCommon Stock | 340 | $13.00 | $4,420.00 |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 2 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 79,821 F2 · kind: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares. F2 · price: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:51 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | OtherCommon Stock | 63,019 | $0.07 | $4,411.33 |
DisclosureSEC source: 0001104659-16-153348 · a4.xml · nonDerivative · entry 1 Lettmann Jason · CIK 0001688269 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 80,161 F2 · price: The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares. F1 · ownership.nature: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX. Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX. MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.